Targeted failure of the week. Post No 115. IMGN901

IMGN901 is an antibody-drug conjugate (ADC) developed by ImmunoGen for the treatment of CD56-positive cancers. Such cancers include small-cell lung cancer (SCLC), Merkel cell carcinoma, many cases of multiple myeloma, and other cancers of neuroendocrine origin. 

And do you know what?

ImmunoGen Inc. (NASDAQ:IMGN) fell $3.14 (19%) to $13.41 on Tuesday after discontinuing on the recommendation of an independent DMC the Phase II NORTH trial, which was evaluating the company's IMGN901 to treat small cell lung cancer (SCLC). The DMC said first-line treatment with IMGN901 plus etoposide and carboplatin was unlikely to demonstrate "sufficient improvement" on the primary endpoint of progression-free survival (PFS) vs. etoposide and carboplatin alone. Additionally, the DMC said all patients should discontinue IMGN901 due to an imbalance in the rate of infection and infection-related deaths between treatment arms. The open-label trial had enrolled over 135 patients with newly diagnosed SCLC.